Merck to Discontinue Osteoporosis Drug Development
Merck has decided to discontinue the development of its osteoporosis drug and will not seek regulatory approval for its use.
Merck (MRK) - Get Report has decided to discontinue the development of its osteoporosis drug and will not seek regulatory approval for its use. The decision follows an independent review of the treatment that confirmed an increased risk of stroke. Merck Research Laboratories President Roger Perlmutter says the drugmaker was disappointed that overall benefit-risk profile for the drug does not support filing or further development.
Employees of TheStreet are restricted from trading individual securities.
